Archer Mark

SEC source: 0001213900-25-106646 · ownership.xml · nonDerivative · entry 2

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By FLG Partners, LLC

Disclosed balance after: 1,255

F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA.

F2 · shares: The RSA of 25,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on November 3, 2025, with 1/4 of such shares to vest on November 3, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter.

F3 · balance_after: On October 24, 2025, the issuer effected a one-for-seven hundred fifty reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F4 · balance_after: The reporting person is a partner at FLG Partners, LLC, but disclaims beneficial ownership of such shares of Common Stock except to the extent of his pecuniary interest therein, and the inclusion of such shares of Common Stock in this report shall not be deemed an admission of beneficial ownership of all such reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001213900-25-106646 · ownership.xml · nonDerivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,806

F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA.

F2 · shares: The RSA of 25,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on November 3, 2025, with 1/4 of such shares to vest on November 3, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter.

F3 · balance_after: On October 24, 2025, the issuer effected a one-for-seven hundred fifty reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001213900-25-026456 · ownership.xml · derivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,742

Underlying: Common Stock · 67,794 shares

Expires 2029-08-05

F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of March 27, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the decrease in the exercise price of certain securities of the issuer to an effective per share price equal to $0.118 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

SEC source: 0001213900-25-015671 · ownership.xml · derivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,948

Underlying: Common Stock · 11,238 shares

Expires 2029-08-05

F1 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

F1 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A common stock purchase warrants (the "Warrants") as of February 18, 2025 pursuant to certain anti-dilution provisions in the Warrants that triggered upon the issuance of securities by the issuer at an effective per share price equal to $0.59 on such date, the consequence of which is that (i) the exercise price of the Warrants decreased to such price and (ii) the number of shares of common stock issuable upon exercise of such Warrants proportionally increased, such that the aggregate exercise price of the Warrants, after taking into account such exercise price decrease, remained equal to the aggregate exercise price at the date of issuance of such Warrants.

SEC source: 0001213900-25-001375 · ownership.xml · nonDerivative · entry 2

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By FLG Partners, LLC

Disclosed balance after: 2,058

F2 · shares: The RSA of 40,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter.

F3 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split and to increase the number of shares of Common Stock directly owned by the reporting person after such acquisition by 160 (on a post-Reverse Stock Split basis) in order to correct an administrative error in the Form 4 filed by the reporting person on August 6, 2024.

F4 · balance_after: The reporting person is a partner at FLG but disclaims beneficial ownership of such shares of Common Stock except to the extent of his pecuniary interest therein, and the inclusion of such shares of Common Stock in this report shall not be deemed an admission of beneficial ownership of all such reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001213900-25-001375 · ownership.xml · nonDerivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,955

F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA.

F2 · shares: The RSA of 40,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on January 2, 2025, with 1/4 of such shares to vest on January 2, 2026, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter.

F3 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split of the issuer's outstanding shares of Common Stock (the "Reverse Stock Split"). The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect the Reverse Stock Split and to increase the number of shares of Common Stock directly owned by the reporting person after such acquisition by 160 (on a post-Reverse Stock Split basis) in order to correct an administrative error in the Form 4 filed by the reporting person on August 6, 2024.

SEC source: 0001213900-24-104155 · ownership.xml · derivative · entry 2

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,710

Underlying: Common Stock · 4,851 shares

Expires 2027-02-05

F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

SEC source: 0001213900-24-104155 · ownership.xml · derivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,710

Underlying: Common Stock · 4,851 shares

Expires 2029-08-05

F1 · security: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · security: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · derivative.exercise_price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · derivative.exercise_price: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F2 · date: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · price: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F1 · derivative.underlying_shares: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · derivative.underlying_shares: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

F1 · balance_after: On November 18, 2024, the issuer effected a one-for-twenty-five reverse stock split (the "Reverse Stock Split") of the issuer's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2 · balance_after: This Form 4 is being filed by the reporting person in order to reflect the acquisition of Series A Common Stock Purchase Warrants (the "Series A Warrants") and Series B Common Stock Purchase Warrants (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants") as of November 26, 2024 pursuant to certain anti-dilution provisions in the Warrants that trigger upon the Reverse Stock Split, the consequence of which is that (i) the exercise prices of the Warrants decrease pursuant to the formula contained in such provisions and (ii) the number of shares of Common Stock issuable upon exercise of the Warrants proportionally increases, such that the aggregate exercise price of each of the Warrants following such adjustments remains equal to the aggregate exercise price of each of such Warrants as of their respective dates of issuance.

SEC source: 0001213900-24-085041 · ownership.xml · derivative · entry 4

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,486

Underlying: Common Stock · 21,486 shares

Expires 2027-02-05

F1 · security: Each of the shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), the Series A Common Stock Purchase Warrants (the "Series A Warrants"), the Series B Common Stock Purchase Warrants (the "Series B Warrants"), and any other securities held by the reporting person that are convertible, exchangeable or exercisable into shares of Common Stock, are subject to the terms and conditions of a lock-up agreement entered into between the issuer (the "Company") and the reporting person, which prevents the offer, sale or other disposition thereof, subject to certain exceptions, for a period of 60 days from the date of the closing of the Company's offering of its securities pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-179133), declared effective by the U.S. Securities and Exchange Commission ("SEC") on August 1, 2024.

F3 · security: This Form 4 amendment is being filed by the reporting person in order to reflect the acquisition by the reporting person of the Series A Warrants and the Series B Warrants on October 1, 2024, the date on which the Company obtained the approval of its stockholders for the issuance of all shares of Common Stock issuable upon exercise of each of the Series A Warrants and Series B Warrants in accordance with Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval"), on which the exercisability of each of the Series A Warrants and the Series B Warrants was conditioned. Accordingly, the dates in Columns 3 and 6 of Table II of the Form 4 filed by the reporting person with the SEC on August 6, 2024 (the "Original Form 4") are hereby amended to October 1, 2024.

F3 · date: This Form 4 amendment is being filed by the reporting person in order to reflect the acquisition by the reporting person of the Series A Warrants and the Series B Warrants on October 1, 2024, the date on which the Company obtained the approval of its stockholders for the issuance of all shares of Common Stock issuable upon exercise of each of the Series A Warrants and Series B Warrants in accordance with Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval"), on which the exercisability of each of the Series A Warrants and the Series B Warrants was conditioned. Accordingly, the dates in Columns 3 and 6 of Table II of the Form 4 filed by the reporting person with the SEC on August 6, 2024 (the "Original Form 4") are hereby amended to October 1, 2024.

F3 · derivative.exercise_date: This Form 4 amendment is being filed by the reporting person in order to reflect the acquisition by the reporting person of the Series A Warrants and the Series B Warrants on October 1, 2024, the date on which the Company obtained the approval of its stockholders for the issuance of all shares of Common Stock issuable upon exercise of each of the Series A Warrants and Series B Warrants in accordance with Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval"), on which the exercisability of each of the Series A Warrants and the Series B Warrants was conditioned. Accordingly, the dates in Columns 3 and 6 of Table II of the Form 4 filed by the reporting person with the SEC on August 6, 2024 (the "Original Form 4") are hereby amended to October 1, 2024.

SEC source: 0001213900-24-085041 · ownership.xml · derivative · entry 3

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,772

Underlying: Common Stock · 62,772 shares

Expires 2029-08-05

F1 · security: Each of the shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), the Series A Common Stock Purchase Warrants (the "Series A Warrants"), the Series B Common Stock Purchase Warrants (the "Series B Warrants"), and any other securities held by the reporting person that are convertible, exchangeable or exercisable into shares of Common Stock, are subject to the terms and conditions of a lock-up agreement entered into between the issuer (the "Company") and the reporting person, which prevents the offer, sale or other disposition thereof, subject to certain exceptions, for a period of 60 days from the date of the closing of the Company's offering of its securities pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-179133), declared effective by the U.S. Securities and Exchange Commission ("SEC") on August 1, 2024.

F3 · security: This Form 4 amendment is being filed by the reporting person in order to reflect the acquisition by the reporting person of the Series A Warrants and the Series B Warrants on October 1, 2024, the date on which the Company obtained the approval of its stockholders for the issuance of all shares of Common Stock issuable upon exercise of each of the Series A Warrants and Series B Warrants in accordance with Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval"), on which the exercisability of each of the Series A Warrants and the Series B Warrants was conditioned. Accordingly, the dates in Columns 3 and 6 of Table II of the Form 4 filed by the reporting person with the SEC on August 6, 2024 (the "Original Form 4") are hereby amended to October 1, 2024.

F4 · derivative.exercise_price: This Form 4 amendment is also being filed by the reporting person to amend the exercise price reported in Column 2 of Table II of the Original Form 4 and the number of shares of Common Stock reported in Columns 5, 7 and 9 of Table II of the Original Form 4 to reflect such information as of the date of Stockholder Approval.

F3 · date: This Form 4 amendment is being filed by the reporting person in order to reflect the acquisition by the reporting person of the Series A Warrants and the Series B Warrants on October 1, 2024, the date on which the Company obtained the approval of its stockholders for the issuance of all shares of Common Stock issuable upon exercise of each of the Series A Warrants and Series B Warrants in accordance with Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval"), on which the exercisability of each of the Series A Warrants and the Series B Warrants was conditioned. Accordingly, the dates in Columns 3 and 6 of Table II of the Form 4 filed by the reporting person with the SEC on August 6, 2024 (the "Original Form 4") are hereby amended to October 1, 2024.

F4 · shares: This Form 4 amendment is also being filed by the reporting person to amend the exercise price reported in Column 2 of Table II of the Original Form 4 and the number of shares of Common Stock reported in Columns 5, 7 and 9 of Table II of the Original Form 4 to reflect such information as of the date of Stockholder Approval.

F3 · derivative.exercise_date: This Form 4 amendment is being filed by the reporting person in order to reflect the acquisition by the reporting person of the Series A Warrants and the Series B Warrants on October 1, 2024, the date on which the Company obtained the approval of its stockholders for the issuance of all shares of Common Stock issuable upon exercise of each of the Series A Warrants and Series B Warrants in accordance with Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval"), on which the exercisability of each of the Series A Warrants and the Series B Warrants was conditioned. Accordingly, the dates in Columns 3 and 6 of Table II of the Form 4 filed by the reporting person with the SEC on August 6, 2024 (the "Original Form 4") are hereby amended to October 1, 2024.

F4 · derivative.underlying_shares: This Form 4 amendment is also being filed by the reporting person to amend the exercise price reported in Column 2 of Table II of the Original Form 4 and the number of shares of Common Stock reported in Columns 5, 7 and 9 of Table II of the Original Form 4 to reflect such information as of the date of Stockholder Approval.

F4 · balance_after: This Form 4 amendment is also being filed by the reporting person to amend the exercise price reported in Column 2 of Table II of the Original Form 4 and the number of shares of Common Stock reported in Columns 5, 7 and 9 of Table II of the Original Form 4 to reflect such information as of the date of Stockholder Approval.

SEC source: 0001213900-24-065854 · ownership.xml · derivative · entry 4

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,486

Underlying: Common Stock · 21,486 shares

Expires 2027-02-05

F1 · security: Each of the shares of the issuer's common stock, par value $0.0001 per share (the "Common Stock"), the issuer's Series A Common Stock Purchase Warrants (the "Series A Warrants"), the issuer's Series B Common Stock Purchase Warrants (the "Series B Warrants"), and any other securities of the issuer (the "Company") held by the reporting person that are convertible, exchangeable or exercisable into shares of Common Stock, are subject to the terms and conditions of a lock-up agreement entered into between the Company and the reporting person, which prevents the offer, sale or other disposition thereof, subject to certain exceptions, for a period of 60 days from the date of the closing of the Company's offering of its securities pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-179133), declared effective by the U.S. Securities and Exchange Commission on August 1, 2024.

F4 · derivative.exercise_date: The Series B Warrants are only exercisable on or after the date of Stockholder Approval.

SEC source: 0001213900-24-065854 · ownership.xml · derivative · entry 3

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,486

Underlying: Common Stock · 21,486 shares

Expires 2029-08-05

F1 · security: Each of the shares of the issuer's common stock, par value $0.0001 per share (the "Common Stock"), the issuer's Series A Common Stock Purchase Warrants (the "Series A Warrants"), the issuer's Series B Common Stock Purchase Warrants (the "Series B Warrants"), and any other securities of the issuer (the "Company") held by the reporting person that are convertible, exchangeable or exercisable into shares of Common Stock, are subject to the terms and conditions of a lock-up agreement entered into between the Company and the reporting person, which prevents the offer, sale or other disposition thereof, subject to certain exceptions, for a period of 60 days from the date of the closing of the Company's offering of its securities pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-179133), declared effective by the U.S. Securities and Exchange Commission on August 1, 2024.

F3 · derivative.exercise_date: The Series A Warrants are only exercisable on or after the date on which the Company obtains the approval of its stockholders for the issuance of all shares of Common Stock issuable upon exercise of each of the Series A Warrants and Series B Warrants solely to the extent such approval is required by Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval").

SEC source: 0001213900-24-065854 · ownership.xml · nonDerivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,856

F1 · security: Each of the shares of the issuer's common stock, par value $0.0001 per share (the "Common Stock"), the issuer's Series A Common Stock Purchase Warrants (the "Series A Warrants"), the issuer's Series B Common Stock Purchase Warrants (the "Series B Warrants"), and any other securities of the issuer (the "Company") held by the reporting person that are convertible, exchangeable or exercisable into shares of Common Stock, are subject to the terms and conditions of a lock-up agreement entered into between the Company and the reporting person, which prevents the offer, sale or other disposition thereof, subject to certain exceptions, for a period of 60 days from the date of the closing of the Company's offering of its securities pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-179133), declared effective by the U.S. Securities and Exchange Commission on August 1, 2024.

SEC source: 0001213900-24-085041 · ownership.xml · nonDerivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,856

F1 · security: Each of the shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), the Series A Common Stock Purchase Warrants (the "Series A Warrants"), the Series B Common Stock Purchase Warrants (the "Series B Warrants"), and any other securities held by the reporting person that are convertible, exchangeable or exercisable into shares of Common Stock, are subject to the terms and conditions of a lock-up agreement entered into between the issuer (the "Company") and the reporting person, which prevents the offer, sale or other disposition thereof, subject to certain exceptions, for a period of 60 days from the date of the closing of the Company's offering of its securities pursuant to the Company's registration statement on Form S-1, as amended (File No. 333-179133), declared effective by the U.S. Securities and Exchange Commission ("SEC") on August 1, 2024.

SEC source: 0001213900-23-065213 · ownership.xml · nonDerivative · entry 2

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By FLG Partners, LLC

Disclosed balance after: 1,441

F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA.

F2 · shares: The RSA of 22,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on July 3, 2023, with 1/4 of such shares to vest on July 3, 2024, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter.

F3 · balance_after: On April 21, 2023, the issuer effected a 1-for-20 reverse stock split of its outstanding shares of Common Stock. The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect such reverse stock split as it pertained to the number of shares of Common Stock that the reporting person held immediately following the grant of the RSA and such reverse stock split, as applicable.

F4 · balance_after: The reporting person is a partner at FLG but disclaims beneficial ownership of such shares of Common Stock except to the extent of his pecuniary interest therein, and the inclusion of such shares of Common Stock in this report shall not be deemed an admission of beneficial ownership of all such reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001213900-23-065213 · ownership.xml · nonDerivative · entry 1

Archer Mark · CIK 0001913913 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,370

F1 · security: Issuable upon the vesting of a restricted stock award ("RSA"), each of which represents the right to receive one share of common stock, par value $0.0001 per share, of the issuer ("Common Stock"), subject to the vesting terms of such RSA.

F2 · shares: The RSA of 22,000 shares of Common Stock was received as compensation for the reporting person's service as an officer pursuant to the issuer's 2023 Stock Incentive Plan. The RSA is subject to vesting commencing on July 3, 2023, with 1/4 of such shares to vest on July 3, 2024, and thereafter, 1/16 of such shares to vest on the first day of each subsequent three-month period until the entire award has vested, so long as the reporting person remains in the service of the issuer for each such quarter.

F3 · balance_after: On April 21, 2023, the issuer effected a 1-for-20 reverse stock split of its outstanding shares of Common Stock. The number of shares of Common Stock reported on this Form 4 have been adjusted to reflect such reverse stock split as it pertained to the number of shares of Common Stock that the reporting person held immediately following the grant of the RSA and such reverse stock split, as applicable.